Travis Wilson

Travis has extensive experience in biotechnology and venture investing, leading transactions from seed investments to near-commercial assets. He has served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy, and ophthalmology.

Prior to joining Gurnet Point Capital, Travis was President and CEO at Stealth BioTherapeutics, a late-stage clinical biotechnology company developing technologies to treat mitochondrial dysfunction in common and rare diseases. For more than a decade, he was a member of the life science investment team at the Morningside Group, a privately-held investment firm. With Morningside, he assisted with multiple financings, including several public and private companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO), and Argos (NASDAQ: ARGS).

Travis has lectured extensively on life science investing and management and is a long-time supporter of patient-advocacy groups. He holds a law degree and a chemical engineering degree, both from the University of Wisconsin.